{"disease":{"id":"hemoglobin","name":"hemoglobin"},"drugs":{"marketed":[{"drug_id":"ravulizumab","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultomiris","generic_name":"RAVULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitor [EPC]","quality_score":75,"revenue":"5100","mechanism":"Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells."},{"drug_id":"crovalimab","indication_name":"paroxysmal nocturnal hemoglobinuria (PNH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piasky","generic_name":"CROVALIMAB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Complement C5 Inhibitor [EPC]","quality_score":62,"revenue":null,"mechanism":"Piasky works by blocking the action of the Complement C5 protein, which is involved in the immune system's response to foreign substances."},{"drug_id":"methylthioninium-chloride","indication_name":"Methemoglobinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Provayblue","generic_name":"methylthioninium chloride","company_name":"","drug_phase":"marketed","molecular_target":"Amine oxidase [flavin-containing] A","drug_class":"Monoamine Oxidase Inhibitors","quality_score":62,"revenue":null,"mechanism":"Provayblue works by inhibiting the enzyme amine oxidase [flavin-containing] A, which is involved in the breakdown of certain amines in the body."},{"drug_id":"eculizumab","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"H5G1.1","generic_name":"ECULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":56,"revenue":null,"mechanism":"Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation."},{"drug_id":"methylene-blue","indication_name":"Diagnosis of methemoglobinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"iptacopan","indication_name":"Paroxysmal Nocturnal Hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fabhalta","generic_name":"IPTACOPAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Factor B","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Iptacopan binds to Factor B, regulating C3 cleavage and downstream effects in the alternative complement pathway, controlling IVH and EVH in PNH and inhibiting local activation in IgAN and C3G."},{"drug_id":"ravulizumab-cwvz","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ULTOMIRIS","generic_name":"RAVULIZUMAB-CWVZ","company_name":"ALEXION PHARM","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"hydroxycarbamide","indication_name":"Hemoglobin SS disease with crisis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamide","company_name":"University of Birmingham","drug_phase":"phase_3","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxycarbamide","indication_name":"Sickling disorder due to hemoglobin S","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamide","company_name":"University of Birmingham","drug_phase":"phase_3","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"siklos","indication_name":"Hemoglobin SS disease with crisis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Siklos","company_name":"Theravia","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"siklos","indication_name":"Sickling disorder due to hemoglobin S","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Siklos","company_name":"Theravia","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ultomiris","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ultomiris","company_name":"Alexion Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylthioninium","indication_name":"Methemoglobinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylthioninium","company_name":"Shandong Cancer Hospital and Institute","drug_phase":"phase_3","molecular_target":"Microtubule-associated protein tau, Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"soliris","indication_name":"Paroxysmal nocturnal hemoglobinuria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Soliris","company_name":"Apellis Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xromi","indication_name":"Hemoglobin SS disease with crisis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xromi","company_name":"Nova Laboratories Limited","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xromi","indication_name":"Sickling disorder due to hemoglobin S","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xromi","company_name":"Nova Laboratories Limited","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxycarbamid","indication_name":"Hemoglobin SS disease with crisis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamid","company_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","drug_phase":"phase_2","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"eculizumab-aeeb","indication_name":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BKEMV","generic_name":"ECULIZUMAB-AEEB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Complement Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"hydroxycarbamid","indication_name":"Sickling disorder due to hemoglobin S","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxycarbamid","company_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","drug_phase":"phase_2","molecular_target":"Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05799118","title":"Study of the Role of Genetic Modifiers in Hemoglobinopathies","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Cyprus Institute of Neurology and Genetics","has_results":false},{"nct_id":"NCT05286138","title":"STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Società Italiana Talassemie ed Emoglobinopatie","has_results":false},{"nct_id":"NCT07305181","title":"Prevalence of Abnormal Haemoglobin Variants in Metropolitan Chattogram, Bangladesh","phase":"","overall_status":"COMPLETED","enrollment_count":8400,"lead_sponsor_name":"Bangladesh Bioscience Research Group","has_results":false},{"nct_id":"NCT01374360","title":"Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry","phase":"","overall_status":"COMPLETED","enrollment_count":6061,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06767722","title":"Effectiveness of a Lifestyle Intervention for Pregnant Women With Abnormal Glucose Metabolism in Early Pregnancy: EAGM Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":3430,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04869319","title":"Electronic Triggers: Messaging After A1C EHR Alert","phase":"","overall_status":"COMPLETED","enrollment_count":2403,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06524726","title":"The International PNH Interest Group PNH Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"International PNH Interest Group","has_results":false},{"nct_id":"NCT04609228","title":"Cardiac Surgery Outcomes in Blood-transfusion Acceptors and no Acceptors","phase":"","overall_status":"UNKNOWN","enrollment_count":1911,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT04029142","title":"Screening for Hemoglobinopathies in Pregnant Women","phase":"","overall_status":"COMPLETED","enrollment_count":1785,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT07102849","title":"Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1400,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06991218","title":"Analysis of the Interaction Between Preoperative Lifestyle and Clinical Characteristics of Cardiac Surgery Patients and Perioperative Complications","phase":"","overall_status":"COMPLETED","enrollment_count":1366,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06903299","title":"Prospective Investigation of Intra-Articular Tranexamic Acid Use in Elective Hip Arthroplasty","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"St. Anne's University Hospital Brno, Czech Republic","has_results":false},{"nct_id":"NCT06958822","title":"Ferric Carboxymaltose Methemoglobinemia Study","phase":"","overall_status":"COMPLETED","enrollment_count":977,"lead_sponsor_name":"Ordu University","has_results":false},{"nct_id":"NCT07180836","title":"Prevalence and Hematological Characteristics of Hemoglobinopathies","phase":"","overall_status":"COMPLETED","enrollment_count":839,"lead_sponsor_name":"Bacha Khan Medical College","has_results":false},{"nct_id":"NCT04573244","title":"Hemoglobin Easy Measurement With Optical Artificial Intelligence","phase":"","overall_status":"COMPLETED","enrollment_count":823,"lead_sponsor_name":"MYOR Ltd.","has_results":false},{"nct_id":"NCT07207551","title":"Prevalence of Hemoglobinopathies Associated With Significant Hb Variants in the Chattogram Region of Bangladesh","phase":"","overall_status":"COMPLETED","enrollment_count":760,"lead_sponsor_name":"Bangladesh Bioscience Research Group","has_results":false},{"nct_id":"NCT06154512","title":"A Real-world, Multi-center, Prospective, Observational Study for PNH in China","phase":"","overall_status":"COMPLETED","enrollment_count":724,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06831799","title":"ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":684,"lead_sponsor_name":"Hospital Universitari Vall d'Hebron Research Institute","has_results":false},{"nct_id":"NCT01997502","title":"Accuracy of Pulse CO-Oximetry Technology in Characterizing Noninvasive SpHb","phase":"","overall_status":"COMPLETED","enrollment_count":621,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT06189417","title":"Effect Of Health Extension Worker-Led Based Interventions on Improving Self-Management Behavior Among Diabetic Patients in Ethiopia","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":560,"lead_sponsor_name":"Debre Berhan University","has_results":false},{"nct_id":"NCT05852184","title":"Hb Scope: A Multi-Center Validation Trial","phase":"","overall_status":"COMPLETED","enrollment_count":504,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT05755867","title":"Global PNH Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Aplastic Anemia and MDS International Foundation","has_results":false},{"nct_id":"NCT06857630","title":"Preoperative Hemoglobin and Acute Kidney Injury in Emergency Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Samsun University","has_results":false},{"nct_id":"NCT05217576","title":"NBM-200 Clinical Study in Blood Donation Setting","phase":"NA","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"OneBlood, Inc.","has_results":false},{"nct_id":"NCT07227155","title":"The HOPE Biobank Resource (BMT CTN 2402 HOPE)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":375,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT04865224","title":"Non-Invasive Estimation of Hemoglobin Levels in Blood Using Combined Deep Learning Methods","phase":"","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Karabuk University","has_results":false},{"nct_id":"NCT00102245","title":"Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes","phase":"","overall_status":"TERMINATED","enrollment_count":334,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT02946463","title":"ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03355222","title":"Using Eggshell Calcium to Mitigate Fluorosis in Ethiopia","phase":"NA","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"University of Saskatchewan","has_results":false},{"nct_id":"NCT04201210","title":"A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":212,"lead_sponsor_name":"University of Regensburg","has_results":false},{"nct_id":"NCT04434092","title":"A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":210,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04747613","title":"Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":208,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05744921","title":"A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":202,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03056040","title":"ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07445997","title":"The Association Between Preoperative HbA1c Levels and Postoperative Acute Kidney Injury in Isolated Coronary Artery Bypass Surgery","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Osman Sila Aydin","has_results":false},{"nct_id":"NCT05776472","title":"A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT03329365","title":"Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT06903234","title":"Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05133531","title":"A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04432584","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":190,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03149289","title":"Hepatitis C Virus Infection in Patients With Hemoglobinopathies","phase":"","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Società Italiana Talassemie ed Emoglobinopatie","has_results":false},{"nct_id":"NCT04330534","title":"First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":false},{"nct_id":"NCT04208529","title":"A Long-term Follow-up Study in Participants Who Received CTX001","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":160,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT03138200","title":"The Role of Central Venous Oxygen Saturation (ScvO2) as an Indicator of Blood Transfusion in the Critically Ill","phase":"NA","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Szeged University","has_results":false},{"nct_id":"NCT05448456","title":"Use of Tranexamic Acid After Vaginal Delivery with Episiotomy a RCT Placebo Control Trail","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Assuta Ashdod Hospital","has_results":false},{"nct_id":"NCT06608862","title":"The Impact of Hormonal Contraceptive Use and Lifestyle Factors on Fracture Risk and Bone Quality in Young Female Adults","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Bundeswehr University Munich","has_results":false},{"nct_id":"NCT03748823","title":"Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":139,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03816514","title":"Noninvasive Hemoglobin Monitoring for Maintaining Hemoglobin Concentration Within the Target Range","phase":"NA","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT00277849","title":"Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}